Literature DB >> 27712033

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.

Veronika Bachanova1, Wael Saber2, Ashley Rosko3, Hai-Lin Wang2, Marcos de Lima4, Brenda Sandmaier5, H Jean Khoury6, Andrew Artz7, Johnathan Brammer8, Christopher Bredeson9, Sherif Farag10, Mohamed Kharfan-Dabaja11, Hillard M Lazarus12, David I Marks13, Rodrigo Martino Bufarull14, Joseph McGuirk15, Mohamed Mohty16, Taiga Nishihori11, Ian Nivison-Smith17, Armin Rashidi18, Olle Ringden19,20, Matthew Seftel21, Daniel Weisdorf22.   

Abstract

Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes. Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55-72) with B-ALL with disease status in CR1 (71%), >CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor (59%) or HLA-matched sibling (32%). Among patients with available cytogenetic data, the Philadelphia chromosome (Ph+) was present in 50%. The 3-year cumulative incidences of nonrelapse mortality (NRM) and relapse were 25% (95% confidence intervals (CI): 20-31%) and 47% (95% CI: 41-53%), respectively. Three-year overall survival (OS) was 38% (95% CI: 33-44%). Relapse remained the leading cause of death accounting for 49% of all deaths. In univariate analysis, 3 year risk of NRM was significantly higher with reduced Karnofsky performance status (KPS <90: 34% (95% CI: 25-43%) versus KPS ≥90 (18%; 95% CI: 12-24%, P = 0.006). Mortality was increased in older adults (66+ vs. 55-60: Relative Risk [RR] 1.51 95% CI: 1.00-2.29, P = 0.05) and those with advanced disease (RR 2.13; 95% CI: 1.36-3.34, P = 0.001). Survival of patients in CR1 yields 45% (95% CI: 38-52%) at 3 years and no relapse occurred after 2 years. We report promising OS and acceptable NRM using RIC HCT in older patients with B-ALL. Disease status in CR1 and good performance status are associated with improved outcomes. Am. J. Hematol. 92:42-49, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27712033      PMCID: PMC5167625          DOI: 10.1002/ajh.24575

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  43 in total

1.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

2.  Standardization of terminology for episodes of hematopoietic stem cell patient transplant care.

Authors:  C Fred LeMaistre; Stephanie Farnia; Stephen Crawford; Joseph McGuirk; Richard T Maziarz; James Coates; Dennis Irwin; Patricia Martin; James L Gajewski
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

3.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

4.  Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).

Authors:  William A Wood; Jennifer Le-Rademacher; Karen L Syrjala; Heather Jim; Paul B Jacobsen; Jennifer M Knight; Muneer H Abidi; John R Wingard; Navneet S Majhail; Nancy L Geller; J Douglas Rizzo; Mingwei Fei; Juan Wu; Mary M Horowitz; Stephanie J Lee
Journal:  Cancer       Date:  2015-10-06       Impact factor: 6.860

5.  Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts.

Authors:  Supriya Gupta Mohile; Carla Velarde; Arti Hurria; Allison Magnuson; Lisa Lowenstein; Chintan Pandya; Anita O'Donovan; Rita Gorawara-Bhat; William Dale
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

6.  Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia.

Authors:  S Lee; N-G Chung; B-S Cho; K-S Eom; Y-J Kim; H-J Kim; C-K Min; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-W Park; C-C Kim
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

Review 7.  Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

8.  Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Authors:  S Nishiwaki; K Miyamura; K Ohashi; M Kurokawa; S Taniguchi; T Fukuda; K Ikegame; S Takahashi; T Mori; K Imai; H Iida; M Hidaka; H Sakamaki; Y Morishima; K Kato; R Suzuki; J Tanaka
Journal:  Ann Oncol       Date:  2013-01-31       Impact factor: 32.976

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

View more
  17 in total

1.  Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Gunjan L Shah; Michael Scordo; Satyajit Kosuri; Diego Adrianzen Herrera; Christina Cho; Sean M Devlin; Taylor Borrill; Dean C Carlow; Scott T Avecilla; Richard C Meagher; Richard J O'Reilly; Ann A Jakubowski; Esperanza B Papadopoulos; Guenther Koehne; Boglarka Gyurkocza; Hugo Castro-Malaspina; Brian C Shaffer; Miguel-Angel Perales; Sergio A Giralt; Roni Tamari
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-22       Impact factor: 5.742

2.  Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.

Authors:  Zinaida Peric; Myriam Labopin; Christophe Peczynski; Emmanuelle Polge; Jan Cornelissen; Ben Carpenter; Mike Potter; Ram Malladi; Jenny Byrne; Harry Schouten; Nathalie Fegueux; Gerard Socié; Montserrat Rovira; Jurgen Kuball; Maria Gilleece; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-05-02       Impact factor: 5.483

Review 3.  Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.

Authors:  Nicholas J Short; Hagop Kantarjian; Elias Jabbour; Farhad Ravandi
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

4.  Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study.

Authors:  Yasuo Mori; Kensuke Sasaki; Yoshikiyo Ito; Takuro Kuriyama; Toshiyuki Ueno; Masanori Kadowaki; Takatoshi Aoki; Takeshi Sugio; Goichi Yoshimoto; Koji Kato; Takahiro Maeda; Koji Nagafuji; Koichi Akashi; Toshihiro Miyamoto
Journal:  Ann Hematol       Date:  2020-11-05       Impact factor: 3.673

5.  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Authors:  Mazyar Shadman; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Filippo Milano; Ang Li; Alexandre V Hirayama; Mohamed L Sorror; Sindhu Cherian; Xueyan Chen; Ryan D Cassaday; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; David G Maloney; Cameron J Turtle
Journal:  Blood Adv       Date:  2019-10-22

6.  Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis.

Authors:  Xinjie Xu; Sifei Chen; Zijing Zhao; Xinyi Xiao; Shengkang Huang; Zhaochang Huo; Yuhua Li; Sanfang Tu
Journal:  Front Oncol       Date:  2021-04-28       Impact factor: 6.244

Review 7.  Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.

Authors:  Aaron T Zhao; Anthony D Sung
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

8.  Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.

Authors:  Matthew Mei; Ni-Chun Tsai; Sally Mokhtari; Monzr M Al Malki; Haris Ali; Amandeep Salhotra; Karamjeet Sandhu; Samer Khaled; Eileen Smith; David Snyder; Guido Marcucci; Stephen J Forman; Vinod Pullarkat; Anthony Stein; Ibrahim Aldoss; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-19       Impact factor: 5.742

9.  Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.

Authors:  Colin Flannelly; Bryan E-Xin Tan; Jian Liang Tan; Colin M McHugh; Chandrika Sanapala; Tara Lagu; Jane L Liesveld; Omar Aljitawi; Michael W Becker; Jason H Mendler; Heidi D Klepin; Wendy Stock; Tanya M Wildes; Andrew Artz; Navneet S Majhail; Kah Poh Loh
Journal:  Biol Blood Marrow Transplant       Date:  2020-09-20       Impact factor: 5.609

10.  Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Authors:  Gabrielle Roth-Guepin; Jonathan Canaani; Annalisa Ruggeri; Myriam Labopin; Juergen Finke; Jan J Cornelissen; Jeremy Delage; Gernot Stuhler; Monserrat Rovira; Mike Potter; Michael Stadler; Hendrik Veelken; Jean Yves Cahn; Matthew Collin; Yves Beguin; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Oncotarget       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.